Clinical Trial Update: A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of AMG 330 in adults with myeloid malignancies, including relapsed/refractory acute myeloid leukemia and MRD-positive AML, has been terminated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AMG 330

Snippet

Sponsor: Amgen | Conditions: Relapsed/Refractory AML, Minimal Residual Disease Positive AML | Phase 1 | Status: TERMINATED | Results posted: 2024-07-31